Stockreport

Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer

Kura Oncology, Inc.  (KURA) 
Last kura oncology, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.kuraoncology.com/investor-relations
PDF – Confirmed partial responses observed in five of six evaluable patients with HRAS mutant HNSCC – – Rate of enrollment increasing with three additional patients enrolle [Read more]